Autotransplantation of Joint Capsule, an Attempt to Desensitize Patients Suffering from Rheumatoid Arthritis

Novotny, Hans

doi:10.1111/j.0954-6820.1948.tb09324.x

Cited by 1 publication

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was then that blood transfusions were first employed as therapy in RA (50). Later, autotransplantation of the joint capsule was performed as a strategy for desensitizing patients with RA (51). Although none of these methods has proven effective or safe and the simplistic concepts underlying their use reflect the relative naïveté of a bygone period, far more specific and evidence-based approaches have now emerged.…”

Section: Will Biological Agents Supplant Systemic Glucocorticoids As mentioning

confidence: 99%

Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?

Smith

Bartalena

2019

European Journal of Endocrinology

View full text Add to dashboard Cite

In this article, the two authors present their opposing points of view concerning the likelihood that glucocorticoids will be replaced by newly developed biological agents in the treatment of active, moderate-to-severe thyroid-associated ophthalmopathy (TAO). TAO is a vexing, disfiguring and potentially blinding autoimmune manifestation of thyroid autoimmunity. One author expresses the opinion that steroids are nonspecific, frequently fail to improve the disease and can cause sometimes serious side effects. He suggests that glucocorticoids should be replaced as soon as possible by more specific and safer drugs, once they become available. The most promising of these are biological agents. The other author argues that glucocorticoids are proven effective and are unlikely to be replaced by biologicals. He reasons that while they may not uniformly result in optimal benefit, they have been proven effective in many reports. He remains open minded about alternative therapies such as biologicals but remains skeptical that they will replace steroids as the first-line therapy for active, moderate-to-severe TAO without head-to-head comparative clinical trials demonstrating superiority. Despite these very different points of view, both authors are optimistic about the availability of improved medical therapies for TAO, either as single agents or in combination. Further, both agree that better treatment options are needed to improve the care of our patients with active moderate-to-severe TAO.

show abstract

Section: Will Biological Agents Supplant Systemic Glucocorticoids As mentioning

confidence: 99%

Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?

Smith

Bartalena

2019

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

Autotransplantation of Joint Capsule, an Attempt to Desensitize Patients Suffering from Rheumatoid Arthritis

Cited by 1 publication

References 12 publications

Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?

Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?

Contact Info

Product

Resources

About